FREQUENCY OF ANAEMIA AND RENAL INSUFFICIENCY IN PATIENTS WITH HEART FAILURE
Abstract
Background: Heart Failure (HF) is a common disease with a high mortality rate. Anaemia and renalfailure (RF) are often present in patients with HF and associated with worse prognosis. Objective of studywas to evaluate the prevalence of anaemia and RF in patients with HF. Methods: Patients admitted inPunjab institute of cardiology Lahore with diagnosis of heart failure were enrolled from February, 2008 toDecember, 2008. Anaemia was defined as haemoglobin levels <13 mg/dl for men and 12 mg/dl forwomen. Renal function was assessed by the glomerular filtration rate (GFR), calculated by the simplifiedformula of the MDRD (Modification of Diet in Renal Disease) study. Results: Of the 276 patientsincluded in this study, 42.03% (116) had anaemia and 38.40% (106) had moderate to severe renal failure(GFR <60 ml/min). Conclusion: The prevalence of anaemia and renal failure was high in this populationand was associated with the severity of the HF (functional classes III and IV).Keywords: Heart failure, anaemia, renal insufficiencyReferences
Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda
M, et al. Guidelines for the diagnosis and treatment of chronic
heart failure: executive summary (update 2005): The Task Force
for the Diagnosis and Treatment of Chronic Heart Failure of the
European Society of Cardiology. Eur Heart J 2005;26:1115–40.
Sales ALF, Villacorta H, Reis L, Mesquita ET. Anemia as a
prognostic factor in a population hospitalized due to
decompensated heart failure. Arq Bras Cardiol 2005;84:237–40.
Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ,
Yusuf S, et al. Renal function as a predictor of outcome in a broad
spectrum of patients with heart failure. Circulation 2006;113:671–8.
Silverberg DS, Wexler D, Blum M, Wollman Y, Iaina A. The
cardio-renal syndrome: does it exist? Nephrol Dial Transplant.
;18(Suppl.8): viii7–viii12.
Gil P, Justo S, Caramelo C. Cardio-renal failure: an emerging
clinical entity. Nephrol Dial Transplant. 2005;20:1780–3.
Silverberg D. Outcomes of anaemia management in renal
insufficiency and cardiac disease. Nephrol Dial Transplant
;18(Suppl 2):ii7–ii12.
Lindenfeld J. Prevalence of anemia and effects on mortality in
patients with heart failure. Am Heart 2005;149:391–401.
Tang Y, Katz SD. Anemia in chronic heart failure: prevalence,
etiology, clinical correlates, and treatment options. Circulation
;113:2454–61.
Silverberg DS, Wexler D, Blum M, Keren G, Sheps D,
Leibovitch E, et al. The use of subcutaneous erythropoietin and
intravenous iron for the treatment of the anemia of severe,
resistant congestive heart failure improves cardiac and renal
function and functional cardiac class, and markedly reduces
hospitalizations. J Am Coll Cardiol 2000;35:1737–44.
Tanner H, Moschovitis G, Kuster GM, Hullin R, Pfiffner D, Hess
OM, et al. The prevalence of anemia in chronic heart failure. Int J
Cardiol 2002;86:115–21.
Anand I, McMurray JJV, Whitmore J, Warren M, Pham A,
McCamish MA, et al. Anemia and its relationship to clinical
outcome in heart failure. Circulation 2004;110:149–54.
O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC,
Roger SD, et al. Clinical correlates and consequences of anemia
in a broad spectrum of patients with heart failure: results of the
Candesartan in Heart Failure: Assessment of Reduction in
Mortality and Morbidity (CHARM) Program. Circulation
;113:986–94.
Latado AL, Passos LC, Darze ES, Lopes AA. Comparison of the
effect of anemia on in-hospital mortality in patients with versus
without preserved left ventricular ejection fraction. Am J Cardiol.
;98:1631–4.
Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as
a risk factor and therapeutic target in heart failure. J Am Coll
Cardiol 2004;44:959–66.
Silverberg DS, Wexler D, Blum M, Schwartz D, Wollman Y,
Iaina A. Erythropoietin should be part of congestive heart failure
management. Kidney Int 2003;87(Suppl):S40–7.
Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia
R, et al. Blunted erythropoietin production and defective iron
supply for erythropoiesis as major causes of anaemia in patients
with chronic heart failure. Eur Heart J 2005;26:2232–7.
Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A,
Hryniewicz K, et al. Hemodilution is common in patients with
advanced heart failure. Circulation 2003;107:226–9.
Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E,
Navis G, et al. Anaemia in chronic heart failure is not only related
to impaired renal perfusion and blunted erythropoietin production,
but to fluid retention as well. Eur Heart J 2007;28:166–71.
Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R,
et al. The effect of correction of mild anemia in severe, resistant
congestive heart failure using subcutaneous erythropoietin and
intravenous iron: a randomized controlled study. J Am Coll
Cardiol 2001;37:1775–80.
Mancini DM, Katz SD, Lamanca J, Hudaihed A, Androne AS.
Effect of erythropoietin on exercise capacity in patients with
moderate to severe chronic heart failure. Circulation
;107:294–9.
Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N,
Kaprielian R, et al. Intravenous iron alone for the treatment of
anemia in patients with chronic heart failure. J Am Coll Cardiol
;48(6):1225–7.
Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D,
Keren G, et al. The effect of correction of anaemia in diabetics
and non-diabetics with severe resistant congestive heart failure
and chronic renal failure by subcutaneous erythropoietin and
intravenous iron. Nephrol Dial Transplant 2003;18(1):141–6.
Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y,
Schwartz D. Anemia, chronic renal disease and congestive heart
failure—the cardio renal anemia syndrome: the need for
cooperation between cardiologists and nephrologists. Int Urol
Nephrol 2006;38:295–310.
Published
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
